Adrian Gottschalk, Foghorn Therapeutics CEO
August 23, 2022 10:17 AM EDTUpdated April 24, 08:38 AM
R&D
FDA+

FDA con­verts Foghorn's par­tial hold on blood can­cer study to a full pause

Tyler Patchen

News Reporter

Foghorn Ther­a­peu­tics’ flag­ship pro­gram has tak­en an­oth­er hit as the FDA has told the com­pa­ny to press hard­er on the brakes for a blood can­cer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times